Boehringer Ingelheim reported success for its dual-acting obesity shot survodutide in a Phase 3 trial, reporting up to 17% weight loss among participants who stayed on treatment through the 76-week evaluation window, compared with about 3% for placebo. The company also said up to 85% of survodutide-treated patients achieved at least 5% weight loss. The therapy, licensed from Zealand Pharma, stimulates GLP-1 and glucagon pathways, aiming to address not only fat loss but also the common clinical challenge of preserving lean body mass seen with weight-loss medications. Boehringer highlighted co-primary objectives and secondary assessments including waist circumference. Analysts signaled focus on safety signals and the completeness of comparative claims, while further readouts are expected for trials in liver disease populations such as MASH before broader commercial conclusions are drawn.